Chronic Endometritis and IVF



Status:Recruiting
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:21 - 35
Updated:2/7/2019
Start Date:March 3, 2016
End Date:March 30, 2022
Contact:Thomas M Price, MD
Email:price067@mc.duke.edu
Phone:919 572-4673

Use our guide to learn which trials are right for you!

The Impact of Chronic Endometritis on IVF Pregnancy and Pregnancy Loss Rates

Background: Embryo quality is known to be a very important determinant to predict the
implantation and pregnancy rate in IVF patients, however, the role of uterine integrity or
endometrial receptivity cannot be overlooked.

Chronic endometritis (CE) is an inflammation of the endometrium diagnosed by the presence of
plasma cells in the endometrial stroma. There is not only no census on the definition of CE,
the current literature on the impact of CE on reproductive outcome is controversial and
consists only of retrospective studies with small sample sizes. Although there is a
presumption that CE is related to poor IVF outcome, this belief has not been proven.

Design: Prospective cohort study

Setting: Infertility clinics of 2 academic medical centers

Patients: Patients between the ages of ≥ 21 and ≤ 35 years old undergoing their first IVF
cycle will be invited to participate.

Main Outcome Measures: The primary outcome will be ongoing pregnancy after 12 weeks estimated
gestational age (EGA) with previously documented fetal cardiac motion. Secondary outcomes
will include pregnancy loss rate as defined by chemical pregnancy, blighted ovum or loss of
fetal cardiac motion before 12 weeks EGA.

Materials and Methods: The cycle prior to IVF, patients will undergo an in-office endometrial
biopsy on cycle days 19-24. Samples will be stained for CD138 and the number of plasma cells
will be quantified. The number of plasma cells in a sample that yields the best sensitivity
and specificity for pregnancy will be determined by a Receiver-Operator-Curve. This number
will then be used as a dichotomous variable to assign categories of "positive for CE" and
"negative for CE." Pregnancy and miscarriage rates will then be determined in the positive
and negative CE sample with Chi Square Analysis. A secondary sub analysis will be performed
to determine pregnancy and miscarriage rates in patients who declined to participate in the
study.

Expected Results: The investigators hypothesize that higher rates of CE will be found in
women failing to conceive with IVF and with subsequent first-trimester miscarriage.


Inclusion Criteria:

- age of ≥ 21 and ≤ 35 years old

- undergoing first IVF cycle

- a diagnosis of ovulatory dysfunction, pelvic factor, male factor, cervical factor or
unexplained infertility

Exclusion Criteria:

- BMI > 40 kg/m2, anti-mullerian hormone (AMH) < 1.0 ng/mL or antral follicle count <10

- previous endometrial ablation

- previous uterine artery embolization

- presence of type 0, 1, 2, 3 fibroid tumor

- presence of type 4 fibroid tumor with a mean diameter of > 4 cm

- presence of uterine anomaly other than arcuate configuration

- presence of an endometrial polyp or endometrial synechiae

- presence of a hydrosalpinx on hysterosalpingography or ultrasound

- positive gonorrhea and chlamydia DNA testing

- Patients on chronic glucocorticoids (except nasal preparations), or using
glucocorticoids for assisted hatching will be excluded.

- Patients on monoclonal antibody preparations directed to TNFα will be excluded.

- Post-enrollment exclusion will include patients receiving any antibiotics, except
prophylaxis for transvaginal oocyte retrieval (TVOR) or glucocorticoids, except nasal
preparations, from the time of endometrial biopsy until initial transvaginal
ultrasound (TVUS) for pregnancy.
We found this trial at
1
site
Durham, North Carolina 27713
Phone: 919-572-4673
?
mi
from
Durham, NC
Click here to add this to my saved trials